Stockreport

Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria

IPSEN SA S/ADR  (IPSEY) 
NASDAQ:AMEX Investor Relations: ipsen.com/investors
PDF Ipsen has decided to pause dosing in the palovarotene trials Based on encouraging therapeutic activity signals observed in preliminary post-hoc analyses and recommendati [Read more]